Dr. Erik Sulman Shares His Experience of Joining NBTS's DDR-C.
NBTS issued $2.7 million in grant dollars last year to researchers like Erik Sulman, MD, PhD, at NYU Langone Health’s Perlmutter Cancer Center.
The unique opportunity to collaborate with other researchers in the field across institutions drew him to join NBTS’s DNA Damage Response Consortium.
Dr. Sulman is an expert in radiation oncology and his lab uses innovative cell line barcoding and glioma stem cell models to assess the potential effectiveness of different DDR-targeting drug combinations.
Dr. Sulman and his team are evaluating promising treatments across all types of aggressive gliomas, including #glioblastoma, #astrocytoma, and the notoriously difficult-to-culture #oligodendroglioma.
Learn more: https://braintumor.org/research/initi...
